Mydecine Innovations Group | Company Profile
NEO : MYCO, OTC : MYCOF
Latest Sector Updates
Mydecine Innovations Group is a biotech and life sciences company seeking to develop and commercialise innovative solutions for treating mental health problems. The company is building out a pipeline of nature-sourced psychedelic -assisted therapeutics, novel compounds, therapy protocols and delivery systems.
In February 2021 Mydecine received approval to list on the NEO exchange and announced a C$17.25m bought deal public offering.
Stock information
Contact Information
Website: https://www.mydecine.com/
Contact Email:hello@mydecineinc.comÂ
Corporate Presentation Link: click here
Latest Mydecine Innovations News
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) — Mydecine ...
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple ...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit: Psychedelic Stigma Fades as ...
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use Mydecine ...
Mydecine to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
DENVER , Oct. 6, 2021 /PRNewswire/ — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health ...
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of mental health disorders and ...
